KCNQ subunits encode for the M current (I KM)
Introduction

K
ϩ channels control neuronal excitability by regulating interspike membrane potential, action potential waveform, and firing frequency. The M current (I KM ) is a slowly activating and noninactivating voltage-dependent K ϩ current that repolarizes the neuronal membrane back toward the K ϩ equilibrium potential (E K ) during long-lasting depolarizing inputs, thus limiting repetitive firing and causing spike-frequency adaptation (Brown and Adams, 1980) . Receptor-dependent regulation of the M current is a primary mechanism by which neurotransmitters control neuronal excitability (Marrion, 1997) . Heteromeric assembly of subunits encoded by two members of the KCNQ gene family, namely KCNQ2 and KCNQ3, recapitulate the functional properties of I KM (Wang et al., 1998) , although KCNQ5 and possibly KCNQ4 subunits might also participate in I KM heterogeneity (Rogawski, 2000) .
I KM plays a crucial role in epileptogenesis; mutations in KCNQ2 or KCNQ3 genes cause benign neonatal familial convulsions, a rare dominantly inherited form of human epilepsy (Jentsch, 2000) . Furthermore, drug-induced enhancement of I KM function may oppose epileptic activity; in fact, the novel anticonvulsant N- [2-amino-4-(4-fluorobenzylamino) -phenyl]-carbamic acid ethyl ester [retigabine (RT)], which is structurally unrelated to currently available antiepileptics, specifically activates voltage-gated K ϩ currents carried by some members of the KCNQ family (Main et al., 2000; Rundfeldt and Netzer, 2000a; Wickenden et al., 2000) . In keeping with a K ϩ channel-opening mechanism, RT hyperpolarized and reduced repetitive firing of entorhinal cortical neurons in cortical slices (Hetka et al., 1999) , inhibited firing of mouse primary cortical neurons (Otto et al., 2002) , and activated native I KM in rat sympathetic neurons (Tatulian et al., 2001) . Together, these studies highlight the role of I KM at the postsynaptic level. However, I KM may also play a relevant presynaptic role; in fact, a drug class known as "cognition enhancers" increases neurotransmitter release by suppressing I KM (for review, see Brown and Yu, 2000) , and immunohistochemical studies have demonstrated a widespread presynaptic distribution of some KCNQ subunits within rodents and the human brain (Cooper et al., 2000 (Cooper et al., , 2001 ).
Because multiple KCNQ-type subunits underlie I KM , the aims of the present study have been: (1) to define the specific influence exerted by I KM -encoding KCNQ subunits in the release of previously taken up 1- [7, 
Materials and Methods
Synaptosomal preparation and release experiments. Synaptosomes were prepared from the hippocampi of adult male rats (Martire et al., 2000) . In experiments with antibodies, these were entrapped into the synaptosomes during hippocampal tissue homogenization (1:100 dilution) (Raiteri et al., 2000) . Synaptosomal pellets were resuspended in a medium containing the following (in mM): 125 NaCl, 3 KCl, 1. Raiteri et al., 2002) . Identical aliquots of the synaptosomal suspension were placed at the bottom of parallel superfusion chambers maintained at 37°C and superfused (0.6 ml/min) with standard medium. In [ 3 H]GABA release experiments, 50 M amino-oxyacetic acid was added to prevent the catabolism of the neurotransmitter. After a 46 min equilibration period, perfusate fractions were collected every 2 min; after collection of the first fraction (to measure basal release), synaptosomes were exposed for 3 min to a medium containing elevated KCl concentrations (9, 15, 30, or 50 mM) plus different test drugs. Neurotransmitter efflux into the samples collected was calculated as a fractional rate. Drug effects were evaluated by determining the integrated area under the time course release curve (AUC) after subtraction of the area corresponding to basal release. Data, expressed as means Ϯ SEM, were analyzed by one-way ANOVA followed by Dunnett's multiple comparison test ( p Ͻ 0.05).
Heterologous expression of KCNQ subunits. KCNQ2 or KCNQ3 subunits were expressed in CHO cells (Wickenden et al., 2000) by transient transfection with KCNQ2 or KCNQ3 cDNA, respectively, using Lipofectamine 2000 (Invitrogen, Milan, Italy). Enhanced green fluorescent protein (Clontech, Palo Alto, CA) was used as a transfection marker. For electrophysiological and biochemical experiments, the cells were seeded on glass coverslips, transfected after 24 hr, and analyzed 1-2 d after transfection.
Electrophysiology. Currents were recorded at room temperature (20 -22°C) using an Axopatch 200A amplifier and pClamp 6.0.4 software (Axon Instruments, Foster City, CA). The "perforated-patch" configuration of the patch-clamp technique was adopted using glass micropipettes of 2-3 M⍀ resistance, because KCNQ2 currents showed a fast "run-down" in the conventional whole-cell mode (Shah et al., 2002) . The extracellular solution contained the following (in mM): 150 NaCl, 2 CaCl 2, 2 KCl, 1 MgCl 2 , 11 glucose, and 10 HEPES, pH 7.4, with NaOH. Increases in [KCl] e were compensated with equimolar decreases in [NaCl] e . The intracellular (pipette) solution contained the following (in mM): 120 KCl, 2 MgCl 2 , 10 EGTA, 10 HEPES, 1 Mg-ATP, and 0.25 mM cAMP, pH 7.3-7.4, with KOH. Nystatin (120 -240 g/ml) was added to this solution immediately before each recording session. KCNQ2 channels were activated by means of voltage ramps from Ϫ100 mV to 0 or ϩ20 mV at a 0.5-1 sec/20 mV speed and a frequency of 0.05 Hz. Given the small volume of the recording chamber (Ϸ200 l) and the fast perfusion speed (1 ml/min), solution exchanges were complete after two to three pulses. To quantify drug effects on KCNQ2 channels, the integrated AUCs of ramp-evoked K ϩ currents recorded from KCNQ2-transfected cells in the presence of drug(s) were expressed as a percentage of the AUCs of ramp-evoked K ϩ currents recorded in control conditions. Indirect immunofluorescence. Cells were fixed with 4% formaldehyde for 20 min at room temperature and permeabilized with 0.1% Triton X-100 in PBS. Cells were labeled with the appropriate primary antibodies (1:200 dilution) followed by rhodamine-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA) and analyzed on an Eclipse 400 photomicroscope (Nikon, Tokyo, Japan) with a 60ϫ objective.
Materials (Fig. 1 A,B 3 H]NE release evoked by exposure to 100 M 4-aminopyridine (4-AP) (AUC, 16.58 Ϯ 1.16%) was also inhibited by RT (E Max , 43.5 Ϯ 2.1%; EC 50 , 1.13 Ϯ 0.05 M; data not shown).
To verify whether RT also inhibited the release of other hippocampal neurotransmitters, we evaluated its effects on the release of glutamate and GABA. To label glutamatergic terminals, [ 3 H]D-ASP was used because it is more resistant to catabolism (Davies and Johnston, 1976) ; furthermore, synaptosomal [ 3 H]D-ASP uptake (Gundersen et al., 1995) and release (Martire et al., 2000) (Fig. 1 B) 3 H]NE release To confirm that M channels were involved in RT-induced inhibition of synaptosomal neurotransmitter release, and to identify the contribution of specific KCNQ subunits, we used commercially available polyclonal antibodies specifically directed against KCNQ2 or KCNQ3 subunits. Immunofluorescence experiments revealed that anti-KCNQ2 antibodies labeled CHO cells transfected with KCNQ2 but not with KCNQ3 cDNAs, whereas the opposite was observed with anti-KCNQ3 antibodies (Fig. 2 A) . In both cases, labeling was abolished by antibody preabsorption with the respective immunizing peptide, arguing in favor of a specific interaction between these antibodies and KCNQ subunits. Notably, these antibodies were also used to detect KCNQ2 and KCNQ3 subunits in immunocytochemistry experiments in native rat hippocampal neurons (Shah et al., 2002) . These results suggest that both antibodies bind to KCNQ subunit epitopes in their native, nondenatured conformation, making them useful tools to dissect the role of KCNQ subunits in synaptosomal [ 3 H]NE release. Because both antibodies recognized intracellular epitopes, we used the synaptosomal entrapping technique, which allows membrane-impermeant proteins to gain access to the synaptosomal cytoplasm (Raiteri et al., 2000) . Synaptosomal entrapment of anti-KCNQ2 antibodies completely prevented 1 M RTinduced inhibition of 9 mM [K ϩ ] e -evoked hippocampal [ 3 H]NE release (Fig. 2 B) , an effect that was abolished after antibody preabsorption, before entrapment, with the KCNQ2 immunizing peptide; in contrast, anti-KCNQ3 antibodies were ineffective. Entrapment of both anti-KCNQ2 and anti-KCNQ3 antibodies also abolished RT-induced inhibition of 9 mM (Fig. 3A) . To investigate whether RT interference with KCNQ2 channels depended on [K ϩ ] e , electrophysiological studies in KCNQ2-transfected CHO cells were performed to assess the effects of RT on KCNQ2 K ϩ channel activity with 2 and 50 mM [K ϩ ] e . In the presence of 2 mM [K ϩ ] e , 10 M RT hyperpolarized the voltage dependence of KCNQ2 K ϩ channel activation by Ϫ19.6 Ϯ 0.9 mV (n ϭ 13) (Fig. 3B) . In fact, KCNQ2 currents reached 10% of the peak at Ϫ40 Ϯ 1.9 mV in controls and at Ϫ60.3 Ϯ 2.2 mV after exposure to 10 M RT ( p Ͻ 0.05) (Fig.  3B) . A similar negative shift of Ϫ16.7 Ϯ 1.6 mV in the voltage dependence of activation of KCNQ2 currents was induced by 10 M RT when 50 mM [K ϩ ] e was used (controls, Ϫ63.8 Ϯ 3.1 mV; 10 M RT, Ϫ80.5 Ϯ 3.6 mV; n ϭ 4; p Ͻ 0.05). Thus, RT (Fig. 3C) . 
Hippocampal [ 3 H]NE release is influenced by I KM modulators
The nonopioid analgesic FP (0.01-30 M), a structural analog of RT (Friedel and Fitton, 1993) , inhibited 9 mM [K ϩ ] e -induced [ 3 H]NE release from hippocampal synaptosomes; when compared with RT, FP appeared to be equipotent (EC 50 , 1.27 Ϯ 0.08 M) but less effective (E Max , 24.7 Ϯ 1.5%) (Fig. 1 B) . Electrophysiological studies in KCNQ2-transfected cells showed that 10 M FP caused a voltage-dependent hyperpolarizing shift in KCNQ2 activation threshold of Ϫ9 Ϯ 1 mV (n ϭ 4), approximately half that caused by RT (Fig. 3C) ; furthermore, just as with RT, maximal FP-induced current enhancement was observed at potentials of approximately Ϫ65 mV (Fig. 3C) .
Low micromolar concentrations of the cognition enhancer XE-991 (Zaczek et al., 1998) specifically inhibit K ϩ channels formed by KCNQ-type subunits (Wang et al., 1998) . XE-991 (10 -100 M) completely prevented the inhibitory effects on 9 mM [K ϩ ] e -induced [ 3 H]NE release exerted by 1 M RT (Fig. 4 A) . These findings are consistent with those obtained in CHO cells, in which XE-991 blocked KCNQ2 K ϩ channels and essentially prevented their activation by RT (Fig. 4 B) . In fact, in the absence of XE-991, the integrated AUCs of ramp-evoked KCNQ2 K ϩ currents were 163.5 Ϯ 9.6 and 211.6 Ϯ 15.9% with 1 and 10 M RT, respectively, compared with control KCNQ2 currents (n ϭ 4; p Ͻ 0.05 vs controls); in the presence of 10 M XE-991, these values were 6.1 Ϯ 2.7, 10.9 Ϯ 2.1, and 12.8 Ϯ 3.6% of control KCNQ2 currents with 0, 1, and 10 M RT, respectively (n ϭ 4; p Ͻ 0.05 vs controls).
M channels containing KCNQ2 subunits are exquisitely sensitive to blockade by submillimolar concentrations of tetraethyl- ) were activated by the voltage-ramp protocol described in Materials and Methods under control conditions (C), after exposure to 10 M RT or to 10 M FP and after washout (W), as indicated in the inset. After normalization to the maximal value, the currents recorded in the presence of the drug were divided by the control currents, and the results were expressed as a function of membrane potential. 
